Nanoradiosensitizer with Good Tissue Penetration and Enhances Oral Cancer Radiotherapeutic Effect

Overview

Journal Biomaterials

Specialty Biomedical Engineering

Date 2022 Sep 9

PMID 36084485

Authors

Di Jing

Nian Jiang

Fengyi Wang

Chunping Mao

Shujun Han

Pui Yan Ho

Wenwu Xiao

Yuanpei Li

Jian Jian Li

Lu Zhang

Kit S Lam

Affiliations

Soon will be listed here.

Abstract

Low dose non-toxic disulfide cross-linked micelle (DCM) encapsulated paclitaxel (PTX) was found to be highly efficacious as a radiosensitizer against oral cancer preclinical model. Intensity-modulated radiation therapy was locally administered for three consecutive days 24 h after intravascular injection of DCM-[PTX] at 5 mg/kg PTX. DCM-[PTX] NPs combined with conventional radiotherapy (2 Gy) resulted in a 1.7-fold improvement in therapeutic efficacy compared to conventional PTX plus radiotherapy. Interestingly, we found that radiotherapy can decrease tight junctions and increase the accumulation of DCM-[PTX] in tumor sites. Stereotactic body radiotherapy (SBRT) given at 6 Gy was used to further investigate the synergistic anti-tumor effect. Tumor tissues were collected to analyze the relationship between the time interval after SBRT and the biodistribution of the nanomaterials. Compared to combination DCM-[PTX] with conventional radiation dose, combination DCM-PTX with SBRT was found to be more efficacious in inhibiting tumor growth.

Citing Articles

Advances in nanoparticle-based radiotherapy for cancer treatment.

He M, Chen S, Yu H, Fan X, Wu H, Wang Y iScience. 2025; 28(1):111602.

PMID: 39834854 PMC: 11743923. DOI: 10.1016/j.isci.2024.111602.

Nano-Drug Delivery Systems in Oral Cancer Therapy: Recent Developments and Prospective.

Zhang Y, Wu Y, Du H, Li Z, Bai X, Wu Y Pharmaceutics. 2024; 16(1).

PMID: 38276483 PMC: 10820767. DOI: 10.3390/pharmaceutics16010007.

References

Pulito C, Cristaudo A, La Porta C, Zapperi S, Blandino G, Morrone A . Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res. 2020; 39(1):210. PMC: 7542970. DOI: 10.1186/s13046-020-01715-7. View

Phillips R, Shi W, Deek M, Radwan N, Lim S, Antonarakis E . Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020; 6(5):650-659. PMC: 7225913. DOI: 10.1001/jamaoncol.2020.0147. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Bahig H, Aubin F, Stagg J, Gologan O, Ballivy O, Bissada E . Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma. BMC Cancer. 2019; 19(1):68. PMC: 6332607. DOI: 10.1186/s12885-019-5266-4. View

Siu L, Brody J, Gupta S, Marabelle A, Jimeno A, Munster P . Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. J Immunother Cancer. 2020; 8(2). PMC: 7549442. DOI: 10.1136/jitc-2020-001095. View

Price L, Rivera J, Madden A, Herity L, Piscitelli J, Mageau S . Minibeam radiation therapy enhanced tumor delivery of PEGylated liposomal doxorubicin in a triple-negative breast cancer mouse model. Ther Adv Med Oncol. 2021; 13:17588359211053700. PMC: 8558804. DOI: 10.1177/17588359211053700. View

Teng F, Tian W, Wang Y, Zhang Y, Guo F, Zhao J . Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J Hematol Oncol. 2016; 9:8. PMC: 4744391. DOI: 10.1186/s13045-015-0231-4. View

Wang H, Tang H, Fang Y, Tan L, Yin J, Shen Y . Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial. JAMA Surg. 2021; 156(5):444-451. PMC: 7970392. DOI: 10.1001/jamasurg.2021.0133. View

Gao R, Teraphongphom N, van den Berg N, Martin B, Oberhelman N, Divi V . Determination of Tumor Margins with Surgical Specimen Mapping Using Near-Infrared Fluorescence. Cancer Res. 2018; 78(17):5144-5154. PMC: 6125224. DOI: 10.1158/0008-5472.CAN-18-0878. View

10.

Li Y, Xiao K, Luo J, Lee J, Pan S, Lam K . A novel size-tunable nanocarrier system for targeted anticancer drug delivery. J Control Release. 2010; 144(3):314-23. PMC: 2878919. DOI: 10.1016/j.jconrel.2010.02.027. View

11.

Huang H, Feng Y, Wan T, Zhang Y, Cao X, Huang Y . Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer: The STARS Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021; 7(3):361-369. PMC: 7809615. DOI: 10.1001/jamaoncol.2020.7168. View

12.

Siva S, Jackson P, Kron T, Bressel M, Lau E, Hofman M . Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a dose-response relationship. Radiother Oncol. 2016; 118(3):540-6. DOI: 10.1016/j.radonc.2016.01.027. View

13.

Kulkarni S, Ghosh S, Hauer-Jensen M, Kumar K . Hematological targets of radiation damage. Curr Drug Targets. 2010; 11(11):1375-85. DOI: 10.2174/1389450111009011375. View

14.

Capote-Moreno A, Brabyn P, Munoz-Guerra M, Sastre-Perez J, Escorial-Hernandez V, Rodriguez-Campo F . Oral squamous cell carcinoma: epidemiological study and risk factor assessment based on a 39-year series. Int J Oral Maxillofac Surg. 2020; 49(12):1525-1534. DOI: 10.1016/j.ijom.2020.03.009. View

15.

Zheng X, Pan D, Chen X, Wu L, Chen M, Wang W . Self-Stabilized Supramolecular Assemblies Constructed from PEGylated Dendritic Peptide Conjugate for Augmenting Tumor Retention and Therapy. Adv Sci (Weinh). 2021; 8(22):e2102741. PMC: 8596125. DOI: 10.1002/advs.202102741. View

16.

Gatta G, Botta L, Sanchez M, Anderson L, Pierannunzio D, Licitra L . Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. Eur J Cancer. 2015; 51(15):2130-2143. DOI: 10.1016/j.ejca.2015.07.043. View

17.

Xiao K, Luo J, Fowler W, Li Y, Lee J, Xing L . A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials. 2009; 30(30):6006-16. PMC: 2735593. DOI: 10.1016/j.biomaterials.2009.07.015. View

18.

Ji X, Zhu X, Lu X . Effect of cancer-associated fibroblasts on radiosensitivity of cancer cells. Future Oncol. 2017; 13(17):1537-1550. DOI: 10.2217/fon-2017-0054. View

19.

Adelstein D, Lavertu P, Saxton J, Secic M, Wood B, Wanamaker J . Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer. 2000; 88(4):876-83. DOI: 10.1002/(sici)1097-0142(20000215)88:4<876::aid-cncr19>3.0.co;2-y. View

20.

Biau J, Thivat E, Millardet C, Saroul N, Pham-Dang N, Molnar I . A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial. BMC Cancer. 2020; 20(1):730. PMC: 7409463. DOI: 10.1186/s12885-020-07231-3. View